R. Von Moos

Discipline

Economies et finances (1)

Type de document

Articles (10) Colloques et conférences (3) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Treatment (12) Patients (12) Patients (12) thérapie (11) Therapeutics (11) procès (10) maladie (9) maladie (9) cancer (8) survie (8) Cancer (8) Survival (8) Cancer (8) Breast (7) Chemotherapy (6) Methods (6) Human beings (6) Chemotherapy (6) Methods (6) toxicité (5) dose (5) taux (5) Months (5) Days (5) Bevacizumab (5) Toxicology (5) sécurité (4) Control (4) Rates (4) Ci (Chinese poetry) (4)

Documents écrit par R. Von Moos (13) | parle de R. Von Moos (0)

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
M. Joerger et al.
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
U. Hasler-Strub et al.
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
E. Schmulenson et al.
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
M. Mark et al.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
J. Mangana et al.
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
R. Dummer et al. (2016)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
R. von Moos et al. (2012)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
C. Rochlitz et al. (2011)
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman et al. (2010)
hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)
K. Zaman et al. (2010)
Can resistance to trastuzumab be reversed by endocrine therapy? Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
D. Koeberle et al. (2010)